Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DRD2 | P14416 | 2/20 | 0.32 |
| ▸ | DRD1 | P21728 | 1/20 | 0.32 |
| ▸ | OR51E2 | Q9H255 | 1/20 | 0.31 |
| ▸ | CRBN | Q96SW2 | 3/20 | 0.31 |
| ▸ | FKBP5 | Q13451 | 1/20 | 0.30 |
| ▸ | DRD4 | P21917 | 1/20 | 0.30 |
| ▸ | DRD3 | P35462 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8275417 | 0.81 | CRBN (0.40) | DRD2DRD1OR51E2CRBNFKBP5 | |
| SCHEMBL3736282 | 0.77 | — | — | |
| SCHEMBL25357416 | 0.73 | DDB1 (0.35) | CRBN | |
| SCHEMBL22650416 | 0.73 | HSD11B1 (0.38) | CRBN | |
| SCHEMBL26621567 | 0.71 | DDB1 (0.51) | CRBN | |
| SCHEMBL316267 | 0.70 | — | — | |
| SCHEMBL7620002 | 0.70 | — | — | |
| SCHEMBL13186512 | 0.70 | — | — | |
| SCHEMBL797263 | 0.69 | MAP3K14 (0.39) | OR51E2CRBNFKBP5 | |
| SCHEMBL4467181 | 0.68 | CRBN (0.37) | OR51E2CRBNFKBP5 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 24 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2026085629-A1 | SUBSTITUTED HETEROCYCLIC COMPOUNDS, COMPOSITIONS COMPRISING THEM AND USES THEREOF | Université de Montréal (CA) | 2026-04-30 | — | — | WO | disclosed |
| EP-4146647-B1 | CDK INHIBITORS | GENENTECH INC (US) | 2026-04-15 | — | — | EP | disclosed |
| US-20250325544-A1 | CDK INHIBITORS | GENENTECH, INC. (US) | 2025-10-23 | — | — | US | disclosed |
| US-20250281487-A1 | CDK INHIBITORS | GENENTECH, INC. (US) | 2025-09-11 | — | — | US | disclosed |
| US-20250275972-A1 | CDK INHIBITORS | GENENTECH, INC. (US) | 2025-09-04 | — | — | US | disclosed |
| US-20250275971-A1 | CDK INHIBITORS | GENENTECH, INC. (US) | 2025-09-04 | — | — | US | disclosed |
| CN-120040446-A | CDK inhibitors | 基因泰克公司 | 2025-05-27 | — | — | CN | disclosed |
| US-12285429-B2 | CDK inhibitors | GENENTECH, INC. (US) | 2025-04-29 | — | — | US | disclosed |
| US-20250064806-A1 | CDK INHIBITORS | GENENTECH, INC. | 2025-02-27 | — | — | US | disclosed |
| CN-118406049-A | CDK inhibitors | 锐格药业公司 | 2024-07-30 | — | — | CN | disclosed |
| US-20230174512-A1 | CDK INHIBITORS | GENENTECH, INC. | 2023-06-08 | — | — | US | disclosed |
| US-20230174512-A1 | CDK INHIBITORS | GENENTECH, INC. | 2023-06-08 | — | — | US | disclosed |
| EP-4146647-A1 | CDK INHIBITORS | Qilu Regor Therapeutics Inc. (CN) | 2023-03-15 | — | — | EP | disclosed |
| CN-115803327-A | CDK inhibitors | 上海齐鲁锐格医药研发有限公司 | 2023-03-14 | — | — | CN | disclosed |
| US-20220296595-A1 | CDK INHIBITORS | GENENTECH, INC. | 2022-09-22 | — | — | US | disclosed |
| CN-114364675-A | CDK inhibitors | 上海齐鲁锐格医药研发有限公司 | 2022-04-15 | — | — | CN | disclosed |
| EP-3966213-A1 | CDK INHIBITORS | Qilu Regor Therapeutics Inc. (CN) | 2022-03-16 | — | — | EP | disclosed |
| WO-2021226140-A1 | CDK INHIBITORS | QILU REGOR THERAPEUTICS INC. (CN) | 2021-11-11 | — | — | WO | disclosed |
| WO-2021226140-A1 | CDK INHIBITORS | QILU REGOR THERAPEUTICS INC. (CN) | 2021-11-11 | — | — | WO | disclosed |
| WO-2020224568-A1 | CDK INHIBITORS | QILU REGOR THERAPEUTICS INC. (CN) | 2020-11-12 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250281487-A1 | CDK INHIBITORS | CDK6, CDK9, CDKL1 | DRD2 3243/4885DRD1 2895/4885OR51E2 3901/4885 |
| US-20250064806-A1 | CDK INHIBITORS | CDK9, CDK6, CDK3 | DRD2 3887/4885DRD1 3336/4885OR51E2 4337/4885 |
| US-12285429-B2 | CDK inhibitors | CDK9, CDK3, CDKL1 | DRD2 3752/4885DRD1 3101/4885OR51E2 4417/4885 |
| US-20250325544-A1 | CDK INHIBITORS | CDK6, CDK9, CDKL1 | DRD2 3243/4885DRD1 2895/4885OR51E2 3901/4885 |
| US-20250275972-A1 | CDK INHIBITORS | CDK9, CDK6, CDK3 | DRD2 3887/4885DRD1 3336/4885OR51E2 4337/4885 |
| US-20220296595-A1 | CDK INHIBITORS | CDKL1, CDK9, CDK6 | DRD2 4100/4885DRD1 3337/4885OR51E2 4562/4885 |
| US-20230174512-A1 | CDK INHIBITORS | CDK9, CDKL1, CDK3 | DRD2 4046/4885DRD1 3390/4885OR51E2 4384/4885 |
| US-20250275971-A1 | CDK INHIBITORS | CDK6, CDK9, CDKL1 | DRD2 3243/4885DRD1 2895/4885OR51E2 3901/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.